Neil Gallagher Biography and Net Worth

President, Head of Research and Development of Syndax Pharmaceuticals

Neil Gallagher, M.D., Ph.D., has served as our President, Head of Research and Development since April 2023.

Neil served as Chief Medical Officer, Vice President, Head of Development at AbbVie from January 2020 to April 2023, where he led multiple development programs through approval globally and oversaw asset strategy and portfolio management across several therapeutic areas. Neil previously served as AbbVie’s Head of Global Oncology Development from November 2017 to December 2019. Prior to joining AbbVie, he served as Head of Development for Oncology and Inflammation at Amgen from May 2016 to October 2017 and spent a decade at Novartis leading several development and clinical programs across the portfolio. Earlier in his career, he was a Senior Medical Director at AstraZeneca and later Director of Clinical Development at Astex Therapeutics. Neil currently serves on the Board of Directors of Zymeworks Inc., a publicly traded biotechnology company, where he also serves as a member of its Research and Development Committee.

Neil received his medical degree from Trinity College, Dublin. Neil completed his Fellowship in Gynecological Oncology at the Institute for Cancer Studies, University of Birmingham, United Kingdom.

What is Neil Gallagher's net worth?: The estimated net worth of Neil Gallagher is at least $1.05 million as of February 10th, 2025. Dr. Gallagher owns 85,095 shares of Syndax Pharmaceuticals stock worth more than $1,048,796 as of March 31st. This net worth evaluation does not reflect any other assets that Dr. Gallagher may own. Learn More about Neil Gallagher's net worth.
How do I contact Neil Gallagher?: The corporate mailing address for Dr. Gallagher and other Syndax Pharmaceuticals executives is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. Syndax Pharmaceuticals can also be reached via phone at (781) 419-1400 and via email at ir@syndax.com. Learn More on Neil Gallagher's contact information.
Has Neil Gallagher been buying or selling shares of Syndax Pharmaceuticals?: Within the last three months, Neil Gallagher has sold $71,579.00 in Syndax Pharmaceuticals stock. Most recently, Neil Gallagher sold 4,618 shares of the business's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a transaction totalling $71,579.00. Following the completion of the sale, the insider now directly owns 85,095 shares of the company's stock, valued at $1,318,972.50. Learn More on Neil Gallagher's trading history.
Who are Syndax Pharmaceuticals' active insiders?: Syndax Pharmaceuticals' insider roster includes Fabrice Egros (Director), Neil Gallagher (President, Head of Research and Development), Keith Goldan (Chief Financial Officer), Pierre Legault (Director), Michael Metzger (COO), William Meury (Director), Michael Meyers (SVP), Briggs Morrison (CEO), Alexander Nolte (CAO), Peter Ordentlich (Insider), and Dennis Podlesak (Director). Learn More on Syndax Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Syndax Pharmaceuticals?: In the last year, Syndax Pharmaceuticals insiders bought shares 1 times. They purchased a total of 1,250 shares worth more than $25,037.50. In the last year, insiders at the sold shares 3 times. They sold a total of 21,683 shares worth more than $336,086.50. The most recent insider tranaction occured on February, 10th when CFO Keith A Goldan sold 3,777 shares worth more than $58,543.50. Insiders at Syndax Pharmaceuticals own 4.1% of the company. Learn More about insider trades at Syndax Pharmaceuticals.
Information on this page was last updated on 2/10/2025.

Neil Gallagher Insider Trading History at Syndax Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/10/2025	Sell	4,618	$15.50	$71,579.00	85,095

Neil Gallagher Buying and Selling Activity at Syndax Pharmaceuticals

Syndax Pharmaceuticals Company Overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $12.28

$12.12

$12.98

50 Day Range

MA: $14.28

$12.28

$16.38

2 Week Range

Now: $12.28

$12.06

$25.07

Volume

2,495,895 shs

Average Volume

1,513,158 shs

Market Capitalization

$1.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92